[go: up one dir, main page]

EA200600829A1 - Новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]-пиридин-3-ил}-(2-хлорфенил)метанона - Google Patents

Новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]-пиридин-3-ил}-(2-хлорфенил)метанона

Info

Publication number
EA200600829A1
EA200600829A1 EA200600829A EA200600829A EA200600829A1 EA 200600829 A1 EA200600829 A1 EA 200600829A1 EA 200600829 A EA200600829 A EA 200600829A EA 200600829 A EA200600829 A EA 200600829A EA 200600829 A1 EA200600829 A1 EA 200600829A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridine
triazol
chlorophenyl
bistriftormethylbenzyl
methanon
Prior art date
Application number
EA200600829A
Other languages
English (en)
Other versions
EA008881B1 (ru
Inventor
Карстен Тимпе
Альфио Боргезе
Дэвид Скотт Коффи
Пэмела Кайе Футман
Стивен Уэйн Педерсен
Сьюзан Мари Реутцель-Эденс
Шелла Ленйонга Тамезе
Карстен Вебер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200600829A1 publication Critical patent/EA200600829A1/ru
Publication of EA008881B1 publication Critical patent/EA008881B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение обеспечивает новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1Н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона, композиции на их основе, их промежуточные соединения, способы их применения, способы их получения и способы получения их промежуточных соединений.
EA200600829A 2003-10-24 2004-10-12 Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона EA008881B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (2)

Publication Number Publication Date
EA200600829A1 true EA200600829A1 (ru) 2006-08-25
EA008881B1 EA008881B1 (ru) 2007-08-31

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600829A EA008881B1 (ru) 2003-10-24 2004-10-12 Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона

Country Status (28)

Country Link
US (1) US7381826B2 (ru)
JP (1) JP4959336B2 (ru)
KR (1) KR100848407B1 (ru)
CN (1) CN1863791B (ru)
AR (1) AR046131A1 (ru)
AT (1) ATE462700T1 (ru)
AU (1) AU2004285855B8 (ru)
BR (1) BRPI0415010B8 (ru)
CA (1) CA2542140C (ru)
CL (2) CL2009001310A1 (ru)
CR (1) CR8353A (ru)
DE (1) DE602004026333D1 (ru)
DK (1) DK1675846T3 (ru)
EA (1) EA008881B1 (ru)
EC (1) ECSP066517A (ru)
ES (1) ES2340772T3 (ru)
HR (1) HRP20100207T1 (ru)
IL (1) IL174926A0 (ru)
MA (1) MA28329A1 (ru)
MY (1) MY157375A (ru)
NO (1) NO335090B1 (ru)
NZ (2) NZ580480A (ru)
PE (1) PE20050481A1 (ru)
PT (1) PT1675846E (ru)
TW (1) TW200524906A (ru)
UA (1) UA82901C2 (ru)
WO (1) WO2005042515A1 (ru)
ZA (1) ZA200603234B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0721069A2 (pt) * 2006-12-20 2014-02-04 Lilly Co Eli Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
PT3265087T (pt) * 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CN111093671A (zh) 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
SI3710000T1 (sl) * 2017-11-17 2025-07-31 Vanda Pharmaceuticals Inc. Tradipitant za uporabo pri zdravljenju gastropareze
EP3801514A1 (en) 2018-06-08 2021-04-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
HRP20250097T1 (hr) 2018-09-28 2025-03-28 Vanda Pharmaceuticals Inc. Primjena tradipitanta kod bolesti kretanja
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
EP3890735A1 (en) * 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
IL295327A (en) 2020-02-25 2022-10-01 Vanda Pharmaceuticals Inc Improved treatment of atopic dermatitis with tradipitant
US20230145932A1 (en) 2020-03-26 2023-05-11 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
EP4637766A1 (en) 2022-12-21 2025-10-29 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
ATE333879T1 (de) * 1996-10-07 2006-08-15 Merck Sharp & Dohme Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
CA2381882C (en) * 1999-08-13 2011-01-25 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
JP2003513095A (ja) * 1999-10-29 2003-04-08 メルク エンド カムパニー インコーポレーテッド タキキニン受容体アンタゴニストの多形
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
ATE384053T1 (de) * 2002-04-26 2008-02-15 Lilly Co Eli Triazolderivate als tachykininrezeptor- antagonisten

Also Published As

Publication number Publication date
BRPI0415010B8 (pt) 2021-05-25
BRPI0415010A8 (pt) 2018-05-08
WO2005042515A1 (en) 2005-05-12
CN1863791A (zh) 2006-11-15
CN1863791B (zh) 2011-12-07
ZA200603234B (en) 2007-07-25
UA82901C2 (en) 2008-05-26
KR20060061388A (ko) 2006-06-07
CA2542140C (en) 2012-05-29
ECSP066517A (es) 2006-10-10
DE602004026333D1 (de) 2010-05-12
ATE462700T1 (de) 2010-04-15
EA008881B1 (ru) 2007-08-31
NZ580480A (en) 2010-02-26
DK1675846T3 (da) 2010-05-31
NZ545917A (en) 2009-11-27
BRPI0415010A (pt) 2006-11-07
PE20050481A1 (es) 2005-09-20
AR046131A1 (es) 2005-11-23
JP2007509143A (ja) 2007-04-12
CR8353A (es) 2006-06-06
MY157375A (en) 2016-06-15
US20070078166A1 (en) 2007-04-05
IL174926A0 (en) 2006-08-20
AU2004285855B8 (en) 2011-04-28
AU2004285855A1 (en) 2005-05-12
CA2542140A1 (en) 2005-05-12
NO20062371L (no) 2006-05-24
PT1675846E (pt) 2010-04-20
KR100848407B1 (ko) 2008-07-28
MA28329A1 (fr) 2006-12-01
CL2009001310A1 (es) 2009-12-04
NO335090B1 (no) 2014-09-08
BRPI0415010B1 (pt) 2019-07-09
ES2340772T3 (es) 2010-06-09
HRP20100207T1 (hr) 2010-05-31
CL2009001311A1 (es) 2009-10-02
TW200524906A (en) 2005-08-01
AU2004285855B2 (en) 2010-12-23
JP4959336B2 (ja) 2012-06-20
US7381826B2 (en) 2008-06-03

Similar Documents

Publication Publication Date Title
EA200600829A1 (ru) Новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]-пиридин-3-ил}-(2-хлорфенил)метанона
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
NO20063129L (no) Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
EA200600535A1 (ru) Полиморфные формы 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил) пиперидин-2,6-диона
NO20083207L (no) Inhibitorer av IAP
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
EA200600594A1 (ru) Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
EA200501236A1 (ru) Аминогетероарильные соединения в качестве ингибиторов протеинкиназ
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
DE60218703D1 (de) (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
ATE554087T1 (de) Neue kinaseinhibitoren
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
BRPI0407841A (pt) inibidores heterocìclicos de quinase
NO20051273L (no) Piperidinylforbindelser som selektivt binder integriner
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20061137L (no) Cyklopropylderivater som NK3-reseptorantagonister

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG MD TM